Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

Seasonal Allergic Rhinitis Clinical Trial

Official title:

Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Range-Finding Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Adult and Adolescent Patients (12 Years and Older) With Seasonal Allergic Rhinitis (SAR)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00854360
• Other study ID #: BDP-AR-201
• Status: Completed
• Phase: Phase 2
• First received: March 2, 2009
• Last updated: April 23, 2012
• Start date: March 2009
• Est. completion date: May 2009

Study information

• Verified date: April 2012
• Source: Teva Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a phase 2, randomized, double-blind, placebo-controlled, parallel-group, 2-week, multi-center, dose-range-finding study in male or female patients (12 years and older) with SAR.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 487
• Est. completion date: May 2009
• Est. primary completion date: May 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years and older

Eligibility

Key Inclusion Criteria:

• Male or female patients 12 years of age and older, as of the Screening Visit (SV).

• General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study.

• A history of SAR to relevant seasonal allergen (tree/grass pollen) for a minimum of two years immediately preceding the study Screening Visit (SV). The SAR must have been of sufficient severity to have required treatment (either continuous or intermittent) in the past and in the investigator's judgment is expected to be exposed to the allergen and require treatment throughout the entire study period.

• A demonstrated sensitivity to relevant tree/grass pollen known to produce SAR through a standard skin prick test. A positive test is defined as a wheal diameter at least 3 mm larger than the control wheal for the skin prick test. Documentation of a positive result within 12 months prior to Screening Visit (SV) is acceptable.

• Other criteria apply

Key Exclusion Criteria:

• Participation in any investigational drug study within the 30 days preceding the Screening Visit (SV) or planned participation in another investigational drug study at any time during this study.

• History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma or surgery, atrophic rhinitis, or rhinitis medicamentosa (all within the last 60 days prior to the SV).

• History of a respiratory infection or disorder [including, but not limited to bronchitis, pneumonia, chronic sinusitis, influenza, severe acute respiratory syndrome (SARS)] within the 14 days preceding the Screening Visit (SV), or development of a respiratory infection during the Run-in Period.

• Use of any prohibited concomitant medications within the prescribed (per protocol) time since the last dosing period prior to the Screening Visit (SV) and/or plans for use during the entire treatment duration.

• Other criteria apply

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hayfever
• Rhinitis
• Rhinitis, Allergic, Seasonal
• Seasonal Allergic Rhinitis

Intervention

Drug:
• Beclomethasone dipropionate HFA Nasal Aerosol
Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
• Placebo
HFA Vehicle Aerosol

Locations

Country	Name	City	State
United States	Teva Global Respiratory Research Study Site	Austin	Texas
United States	Teva Global Respiratory Research Study Site	Bethesda	Maryland
United States	Teva Global Respiratory Research Study Site	Blue Bell	Pennsylvania
United States	Teva Global Respiratory Research Study Site	Brick	New Jersey
United States	Teva Global Respiratory Research Study Site	Burke	Virginia
United States	Teva Global Respiratory Research Study Site	Charleston	South Carolina
United States	Teva Global Respiratory Research Study Site	Colorado Springs	Colorado
United States	Teva Global Respiratory Research Study Site	Dallas	Texas
United States	Teva Global Respiratory Research Study Site	Denver	Colorado
United States	Teva Global Respiratory Research Study Site	Draper	Utah
United States	Teva Global Respiratory Research Study Site	Gainesville	Georgia
United States	Teva Global Respiratory Research Study Site	Indianapolis	Indiana
United States	Teva Global Respiratory Research Study Site	Medford	Oregon
United States	Teva Global Respiratory Research Study Site	Mission Viejo	California
United States	Teva Global Respiratory Research Study Site	New Braunfels	Texas
United States	Teva Global Respiratory Research Study Site	Overland Park	Kansas
United States	Teva Global Respiratory Research Study Site	Pittsburgh	Pennsylvania
United States	Teva Global Respiratory Research Study Site	Portland	Oregon
United States	Teva Global Respiratory Research Study Site	Raleigh	North Carolina
United States	Teva Global Respiratory Research Study Site	Richmond	Virginia
United States	Teva Global Respiratory Research Study Site	San Antonio	Texas
United States	Teva Global Respiratory Research Study Site	San Diego	California
United States	Teva Global Respiratory Research Study Site	San Diego	California
United States	Teva Global Respiratory Research Study Site	Savannah	Georgia
United States	Teva Global Respiratory Research Study Site	St. Louis	Missouri
United States	Teva Global Respiratory Research Study Site	Upland	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Teva Branded Pharmaceutical Products, R&D Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period	Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 12 hours twice daily (AM & PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptoms hard to tolerate, interfere with daily activities and/or sleeping).; The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)	No
Secondary	Change From Baseline in Average AM and PM Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two Week Treatment Period	Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the 10 minutes prior to the assessment, twice daily (AM & PM) using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities and/or sleeping). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)	No
Secondary	Change From Baseline in Morning Instantaneous Total Nasal Symptom Score (iTNSS) Over the Two-week Treatment Period	Change from Baseline in the morning patient-reported instantaneous TNSS. Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) over the past 10 minutes (prior to the assessment) in the morning on a scale from 0 (mild symptoms) to 3 (severe symptoms). The total nasal symptom score (sum of the 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)	No
Secondary	Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)	The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7. A negative change from Baseline score indicates symptom improvement.	Baseline and Week 2	No
Secondary	Change From Baseline in Morning 24-hour Reflective Ocular Symptom Score Over the Two-week Treatment Period	Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes and redness of eyes) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptoms); 1=mild (sign/symptom present, minimal awareness, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (sign/symptom hard to tolerate, interfere with daily activities or sleeping).; The total ocular symptom score (sum of 3 symptom scores) ranges from 0 to 9 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)	No
Secondary	Change From Baseline in Morning 24-hour Reflective Non-nasal Symptom Score Over the Two-week Treatment Period	Participants recorded the severity of their symptoms (itching/burning eyes, tearing/watering eyes, redness of eyes and itching of ears or palate) for the past 24 hours each morning using the following scale: 0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (awareness of sign/symptom, bothersome but tolerable); 3=severe (symptoms hard to tolerate, interfere with daily activities or sleeping).; Total non-nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from Baseline score indicates symptom improvement.	Baseline (Day -6 to 0) and Days 1-15 (2-week Treatment Period)	No